Colorectal Cancer | Specialty

CRC Biomarkers Exert Growing Influence on Prognosis and Treatment

September 2nd 2016

Molecular testing for colorectal cancer continues to evolve at a rapid pace. Biomarkers already have the potential to predict outcomes and better target therapies, with the eventual goal to completely personalize treatments based on the patient’s individual biomarker profile and other tumor markers.

Dr. Sharma on Tolerability of SIRT in Patients With CRC

September 1st 2016

Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the safety profile of selective internal radiation therapy (SIRT) when added to chemotherapy for patients with colorectal cancer (CRC) that has metastasized to the liver.

Marshall Discusses Role of Regorafenib in Second-Line mCRC Care

August 29th 2016

John L. Marshall, MD, discusses second-line treatment options for patients with metastatic colorectal cancer, along with who is most appropriate to receive regorafenib (Stivarga) and how to manage doses and toxicities when using the multikinase inhibitor.

Study Calls for Interventions to Increase Colorectal Cancer Screening in Hispanic Men

August 28th 2016

Colorectal cancer mortality rates have been on the decline in California for both men and women since the mid-1990s, but for one group—Hispanic men—rates have remained essentially unchanged, and a new study suggests that lower rates of screening may be the chief driver of this disparity.

Dr. Matthew Yurgelun on Next Steps in Understanding CRC Mutations

August 26th 2016

Dr. Heinemann on Using Depth of Response in Pretreated Patients With CRC

August 22nd 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses using depth of response as an appropriate endpoint in studies examining patients with metastatic colorectal cancer (mCRC).

Dr. Michael J. Overman on Immunotherapy in Colorectal Cancer

August 19th 2016

Dr. Paty on Patients With Rectal Cancer Ineligible for "Watch and Wait"

August 17th 2016

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses patients with rectal cancer who are ineligible for a "watch and wait" approach with their surgeons.

Dr. Filippo Pietrantonio on Using Nomogram for Patient Selection in CRC Trials

August 11th 2016

Colorectal Cancer: Patient Follow-Up with Trifluridine/Tipiracil

August 10th 2016

Colorectal Cancer: Patient Follow-Up with Regorafenib

August 10th 2016

Regorafenib in Colorectal Cancer: Optimizing the Dose

August 10th 2016

Practical Advice for Using Trifluridine/Tipiracil

August 10th 2016

Practical Advice for Using Regorafenib

August 10th 2016

When You Have Decided to Prescribe Trifluridine/Tipiracil

August 10th 2016

When You Have Decided to Prescribe Regorafenib

August 10th 2016

Treatment Approach in Refractory Colorectal Cancer

August 10th 2016

Colorectal Cancer: Georgetown University's Team Approach

August 10th 2016

Expert Explains Significance of Early Tumor Shrinkage in Metastatic Colorectal Cancer

August 10th 2016

Volker Heinemann, MD, PhD, discusses the connection between early tumor shrinkage and overall survival, depth of response, and what it could mean for the future of metastatic colorectal cancer treatment.

Dr. Yurgelun on Educating Patients on Genetic Testing for CRC

August 4th 2016

Matthew Yurgelun, MD, instructor in medicine, Harvard Medical School, Dana-Farber Cancer Institute, explains why oncologists should discuss genetic testing with their patients and family members for colorectal cancer, as well as some of the common risk factors for the disease.